Published in Hum Mol Genet on February 12, 2004
Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature (2010) 5.08
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron (2010) 3.15
The many faces of tau. Neuron (2011) 2.89
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet (2009) 2.69
Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One (2010) 2.49
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem (2010) 2.21
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res (2010) 2.07
Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci (2009) 2.05
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci (2012) 1.95
CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol Cell Biol (2008) 1.82
Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum Mol Genet (2011) 1.72
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov (2011) 1.71
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.70
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A (2008) 1.66
Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58
Regulation of proteasome activity in health and disease. Biochim Biophys Acta (2013) 1.52
Pharmacological targeting of the Hsp70 chaperone. Curr Top Med Chem (2009) 1.51
Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A (2007) 1.50
Allosteric drugs: the interaction of antitumor compound MKT-077 with human Hsp70 chaperones. J Mol Biol (2011) 1.49
The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med (2008) 1.46
The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J Biol Chem (2012) 1.44
CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem (2008) 1.43
Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem (2008) 1.42
The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule. J Neurosci (2009) 1.38
Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther (2009) 1.38
Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem (2008) 1.38
Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol (2012) 1.37
Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest (2008) 1.37
Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med (2015) 1.29
The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.27
Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem (2008) 1.24
Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem J (2006) 1.22
Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol (2008) 1.21
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Ataxia and hypogonadism caused by the loss of ubiquitin ligase activity of the U box protein CHIP. Hum Mol Genet (2013) 1.17
Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nat Commun (2014) 1.17
A novel calcium-binding protein is associated with tau proteins in tauopathy. J Neurochem (2008) 1.16
A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem (2010) 1.15
Tau in physiology and pathology. Nat Rev Neurosci (2015) 1.15
Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. Neurobiol Dis (2005) 1.13
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest (2013) 1.12
Identification of novel genes that modify phenotypes induced by Alzheimer's beta-amyloid overexpression in Drosophila. Genetics (2008) 1.11
Tau and neurodegenerative disease: the story so far. Nat Rev Neurol (2015) 1.10
Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol (2014) 1.09
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One (2009) 1.07
Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J (2012) 1.07
Hsc70 rapidly engages tau after microtubule destabilization. J Biol Chem (2010) 1.06
Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry (2011) 1.05
Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet (2013) 1.05
Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord Drug Targets (2010) 1.04
Tau and tauopathies. Prog Mol Biol Transl Sci (2012) 1.04
Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol (2012) 1.03
Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Front Neurol (2013) 1.03
NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. Hum Mol Genet (2011) 1.02
Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. Neurobiol Dis (2010) 1.02
Hsp70 structure, function, regulation and influence on yeast prions. Protein Pept Lett (2009) 1.01
The ubiquitin ligase E6-AP is induced and recruited to aggresomes in response to proteasome inhibition and may be involved in the ubiquitination of Hsp70-bound misfolded proteins. J Biol Chem (2009) 1.00
Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener (2014) 1.00
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem (2009) 1.00
Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet (2012) 1.00
Pharmacological induction of the heat shock response improves myelination in a neuropathic model. Neurobiol Dis (2008) 1.00
Chaperone signalling complexes in Alzheimer's disease. J Cell Mol Med (2009) 0.99
Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem (2012) 0.99
The Chemical Biology of Molecular Chaperones--Implications for Modulation of Proteostasis. J Mol Biol (2015) 0.98
Salt stress-induced disassembly of Arabidopsis cortical microtubule arrays involves 26S proteasome-dependent degradation of SPIRAL1. Plant Cell (2011) 0.97
Combined pharmacological induction of Hsp70 suppresses prion protein neurotoxicity in Drosophila. PLoS One (2014) 0.96
Loss of Hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta. Mol Cell Biol (2010) 0.95
Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol (2012) 0.94
Ubiquitin pathways in neurodegenerative disease. Front Mol Neurosci (2014) 0.93
Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One (2012) 0.93
Protein homeostasis, aging and Alzheimer's disease. Mol Neurobiol (2012) 0.93
Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. Cell Death Dis (2014) 0.93
Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem J (2014) 0.93
Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies. Future Med Chem (2011) 0.92
Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other Neurodegenerative Diseases. Mol Cell Pharmacol (2010) 0.91
Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A. Proc Natl Acad Sci U S A (2014) 0.91
Molecular chaperones and neuronal proteostasis. Semin Cell Dev Biol (2015) 0.91
The Hsc/Hsp70 co-chaperone network controls antigen aggregation and presentation during maturation of professional antigen presenting cells. PLoS One (2011) 0.91
NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies. PLoS Biol (2016) 0.90
SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci U S A (2014) 0.90
Barcoding heat shock proteins to human diseases: looking beyond the heat shock response. Dis Model Mech (2014) 0.90
Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci (2014) 0.89
Defining an Embedded Code for Protein Ubiquitination. J Proteomics Bioinform (2009) 0.88
Increased E4 activity in mice leads to ubiquitin-containing aggregates and degeneration of hypothalamic neurons resulting in obesity. J Biol Chem (2010) 0.88
Tau alternative splicing and frontotemporal dementia. Alzheimer Dis Assoc Disord (2005) 0.88
Ancient origin of animal U-box ubiquitin ligases. BMC Evol Biol (2010) 0.87
HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease. J Neurochem (2009) 0.87
The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. J Biol Chem (2011) 0.87
Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry (2012) 0.87
Examining the mechanisms that link β-amyloid and α-synuclein pathologies. Alzheimers Res Ther (2012) 0.87
Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin. Biomed Res Int (2014) 0.87
Dealing with misfolded proteins: examining the neuroprotective role of molecular chaperones in neurodegeneration. Molecules (2010) 0.86
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 8.41
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Parkinson's disease. Lancet (2009) 6.60
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci (2005) 5.93
Toxic proteins in neurodegenerative disease. Science (2002) 5.82
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet (2006) 5.50
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell (2011) 4.00
Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ (2010) 3.98
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol (2007) 3.93
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci (2005) 3.92
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging (2011) 3.83
Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet (2012) 3.80
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72
Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol (2013) 3.70
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol (2009) 3.62
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol (2010) 3.61
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci (2007) 3.52
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A (2006) 3.47
Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet (2008) 3.42
Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A (2006) 3.41
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.33
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol Aging (2011) 3.27
Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun (2011) 3.23
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci (2005) 3.20
The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord (2007) 3.04
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest (2006) 2.86
A hierarchical NGF signaling cascade controls Ret-dependent and Ret-independent events during development of nonpeptidergic DRG neurons. Neuron (2007) 2.83
Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem (2011) 2.82
Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet (2005) 2.72
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res (2008) 2.70
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron (2002) 2.65
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci (2010) 2.60
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med (2012) 2.58
Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci (2004) 2.57
Thyroid hormone action in the heart. Endocr Rev (2005) 2.57
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord (2002) 2.56
Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol (2008) 2.56
Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci (2007) 2.55
The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain (2006) 2.52
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51